<DOC>
	<DOCNO>NCT02217644</DOCNO>
	<brief_summary>- Investigation safety tolerability BI 653048 H3PO4 follow administration single rise dos aqueous solution healthy male subject - Pharmacokinetic pharmacodynamic characteristic BI 653048 , include investigation dose proportionality - Investigation relative bioavailability capsule versus aqueous solution</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics BI 653048 H3PO4 Oral Drinking Solution Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Healthy male accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( blood pressure ( BP ) , pulse rate ( PR ) ) , 12lead electrocardiogram ( ECG ) , clinical laboratory test Age ≥21 year ≤50 year Body Mass Index ( BMI ) ≥18.5 kg/m2 BMI ≤29.9 kg/m2 Signed date write informed consent prior admission trial accordance Good Clinical Practice ( GCP ) local legislation Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 h ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within 2 month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL within 4 week prior administration trial ) Excessive physical activity ( within 1 week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) A history additional risk factor Torsades de Pointes ( e.g. , heart failure , hypokalaemia , family history Long QT Syndrome ) Not willing use adequate contraception ( condom use plus another form contraception e.g. , spermicide , oral contraceptive take female partner , sterilisation , intrauterine device ) whole trial period time first intake trial drug 3 month last intake</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>